Showing results (1-10 of 376) with videos related to
Sort By:
Pageof 38
The Oncologist|November 23, 2023
Perspectives on the Treatment of Multiple MyelomaAbdul Rafae, Frits van Rhee, Samer Al HadidiOncotargets and Therapy|June 26, 2023
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current PerspectivesTrilok Shrivastava, Frits Van Rhee, Samer Al HadidiCurrent Oncology Reports|February 12, 2025
Current State of Evidence on Definitions and Management of High-Risk Multiple MyelomaBhavesh Mohan Lal, Frits van Rhee, Samer Al HadidiClinical Lymphoma, Myeloma & Leukemia|July 13, 2024
Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple MyelomaTanvi H Patel, Frits van Rhee, Samer Al HadidiJAMA Network Open|April 20, 2022
Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant NeoplasmsSamer Al Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, et al.Ejhaem|June 19, 2024
B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myelomaAsis Shrestha, Marah Alzubi, Jawad Alrawabdeh, et al.Journal of Cancer Policy|July 19, 2023
Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelinesSuhib Fahmawi, Carolina Schinke, Sharmilan Thanendrarajan, et al.JAMA Network Open|August 26, 2022
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple MyelomaRaghad Alqazaqi, Carolina Schinke, Sharmilan Thanendrarajan, et al.American Journal of Hematology|March 31, 2022
First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysisHassan Abushukair, Sebawe Syaj, Obada Ababneh, et al.Pageof 38